Objectives Carbapenemases, that hydrolyse most b-lactams, have emerged and spread worldwide. Currently are not many data of CPE in CF. The accesses to different hospitals, such as transplant centres, make these patients at high risk for transmission of CPE. The study aims to quantify and describe the CPE isolated from CF patients in a year about active surveillance. Methods During 2014, 147 rectal swabs were analyzed. The swabs were inoculated on McConkey agar plate with meropenem disk. The susceptibility testing was performed with automatic method (Phoenix). Carbapenemase were tested by disk diffusion synergy test. For molecular characterization was used GeneXpert. The fingerprinting of isolates were performed by Box-PCR. Results In ten samples we not evaluated the CPE because there was no bacterial growth. Three patients were colonized by CPE identified as E. cloacae. Clonal identity among strains was founded. The strains show a reduced susceptibility to carbapenems and the resistance to other b-lactams and aminoglycosides. The strains were susceptibility to fluoroquinolones, colistin and tigecycline. The molecular assay shows the presence of bla VIM gene. Conclusion The screening using culture methods has unsuitable for some CF patients while molecular method has more effective. Moreover the genotyping suggests a spread among patients. The CPE represents a danger for CF patients: this resistance may be transmitted to the multi-resistant pathogens that support CF pulmonary infection. Then an active surveillance, with an appropriate method of screening for CF patients, is needed to decrease and prevent the transmission of CPE.